Stem Cell Therapeutics Corp. Announces Shareholder Meeting

Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) wishes
to invite shareholders to a meeting and hear about upcoming events and
milestones.




WHEN:     Monday, October 25, 2010 at 3:00pm MST
                                                
WHERE:    The Calgary Petroleum Club            
          Cardium Room                          
          319 Fifth avenue SW                   
          Calgary, Alberta                      
          Canada T2P 0L5                        



About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.


To view the map associated with this press release, please see the following
link: http://media3.marketwire.com/docs/1021sss.pdf